Abstract
Behçet’s disease (BD) is a systemic vasculitis affecting prominently the veins, which is usually diagnosed in adulthood, but can occur in children younger than 16 years in about 4–26% of cases. The therapy is based on several immune-suppressive drugs; in case of inadequate control and/or complications, the biologic therapy with anti-TNF drugs has been successfully used in adults. Here, we reported one pediatric case of BD with systemic (persistent/recurrent high fever), skin and mucosal manifestations (recurrent aphthous stomatitis, anal/penile ulcers, erythema nodosum and papulo-pustules), that were unresponsive to the conventional treatment with steroids and colchicine; however, he was successfully treated with adalimumab. Compared to adult patients, the experience with adalimumab in the treatment of pediatric BD is very limited. Indeed, through a systematic search in the medical literature, we retrieved 4 case reports and 2 case series, describing BD pediatric patients treated with adalimumab, in addition to three clinical studies including some BD children. The analysis and discussion of these available clinical experiences may indicate adalimumab as an effective and safe option to treat several forms of BD, in addition to BD-related chronic uveitis.
| Original language | English |
|---|---|
| Pages (from-to) | 1107-1112 |
| Number of pages | 6 |
| Journal | Rheumatology International |
| Volume | 39 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun 1 2019 |
Fingerprint
Keywords
- Adalimumab
- Behçet’s disease
- Pediatric rheumatology
ASJC Scopus subject areas
- Rheumatology
- Immunology and Allergy
- Immunology
Cite this
Adalimumab in the treatment of pediatric Behçet’s disease : case-based review. / Poddighe, Dimitri; Mukusheva, Zaure; Dauyey, Kaisar; Assylbekova, Maikesh.
In: Rheumatology International, Vol. 39, No. 6, 01.06.2019, p. 1107-1112.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Adalimumab in the treatment of pediatric Behçet’s disease
T2 - case-based review
AU - Poddighe, Dimitri
AU - Mukusheva, Zaure
AU - Dauyey, Kaisar
AU - Assylbekova, Maikesh
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Behçet’s disease (BD) is a systemic vasculitis affecting prominently the veins, which is usually diagnosed in adulthood, but can occur in children younger than 16 years in about 4–26% of cases. The therapy is based on several immune-suppressive drugs; in case of inadequate control and/or complications, the biologic therapy with anti-TNF drugs has been successfully used in adults. Here, we reported one pediatric case of BD with systemic (persistent/recurrent high fever), skin and mucosal manifestations (recurrent aphthous stomatitis, anal/penile ulcers, erythema nodosum and papulo-pustules), that were unresponsive to the conventional treatment with steroids and colchicine; however, he was successfully treated with adalimumab. Compared to adult patients, the experience with adalimumab in the treatment of pediatric BD is very limited. Indeed, through a systematic search in the medical literature, we retrieved 4 case reports and 2 case series, describing BD pediatric patients treated with adalimumab, in addition to three clinical studies including some BD children. The analysis and discussion of these available clinical experiences may indicate adalimumab as an effective and safe option to treat several forms of BD, in addition to BD-related chronic uveitis.
AB - Behçet’s disease (BD) is a systemic vasculitis affecting prominently the veins, which is usually diagnosed in adulthood, but can occur in children younger than 16 years in about 4–26% of cases. The therapy is based on several immune-suppressive drugs; in case of inadequate control and/or complications, the biologic therapy with anti-TNF drugs has been successfully used in adults. Here, we reported one pediatric case of BD with systemic (persistent/recurrent high fever), skin and mucosal manifestations (recurrent aphthous stomatitis, anal/penile ulcers, erythema nodosum and papulo-pustules), that were unresponsive to the conventional treatment with steroids and colchicine; however, he was successfully treated with adalimumab. Compared to adult patients, the experience with adalimumab in the treatment of pediatric BD is very limited. Indeed, through a systematic search in the medical literature, we retrieved 4 case reports and 2 case series, describing BD pediatric patients treated with adalimumab, in addition to three clinical studies including some BD children. The analysis and discussion of these available clinical experiences may indicate adalimumab as an effective and safe option to treat several forms of BD, in addition to BD-related chronic uveitis.
KW - Adalimumab
KW - Behçet’s disease
KW - Pediatric rheumatology
UR - http://www.scopus.com/inward/record.url?scp=85065461500&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065461500&partnerID=8YFLogxK
U2 - 10.1007/s00296-019-04300-0
DO - 10.1007/s00296-019-04300-0
M3 - Article
VL - 39
SP - 1107
EP - 1112
JO - Rheumatology International
JF - Rheumatology International
SN - 0172-8172
IS - 6
ER -